Trial Profile
A NON-RANDOMIZED, OPEN-LABEL, THREE-PART, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF ITRACONAZOLE, CARBAMAZEPINE, AND QUINIDINE ON THE PHARMACOKINETICS AND SAFETY OF EDP-235 IN HEALTHY PARTICIPANTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Carbamazepine (Primary) ; EDP-235 (Primary) ; Itraconazole (Primary) ; Quinidine (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 26 Apr 2023 Status changed from recruiting to completed.
- 28 Oct 2022 New trial record